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Protein and protein-lipid interactions, with and within specific areas in the cell membrane, are critical in 
order to modulate the cell signaling events required to maintain cell functions and viability. Biological 
bilayers are complex, dynamic platforms, and thus in vivo observations usually need to be preceded by 
studies on model systems that simplify and discriminate the different factors involved in lipid-protein 
interactions. Fluorescence microscopy studies using giant unilamellar vesicles (GUVs) as membrane model 
systems provide a unique methodology to quantify protein binding, interaction, and lipid solubilization in 
artificial bilayers. The large size of lipid domains obtainable on GUVs, together with fluorescence microscopy 
techniques, provides the possibility to localize and quantify molecular interactions. Fluorescence Correlation 
Spectroscopy (FCS) can be performed using the GUV model to extract information on mobility and 
concentration. Two-photon Laurdan Generalized Polarization (GP) reports on local changes in membrane 
water content (related to membrane fluidity) due to protein binding or lipid removal from a given lipid 
domain. In this review, we summarize the experimental microscopy methods used to study the interaction of 
human apolipoprotein A-I (apoA-I) in lipid-free and lipid-bound conformations with bilayers and natural 
membranes. Results described here help us to understand cholesterol homeostasis and offer a 
methodological design suited to different biological systems.
© 2010 Elsevier B.V. All rights reserved.
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1. Introduction
Biological bilayers, such as plasma membranes, offer a unique 
platform in which a dynamic arrangement of lipids regulates the 
molecular interactions involved in cellular functions. Small changes 
such as cholesterol content and fluidity could induce growing or 
coalescence of microdomains that, as a consequence, favor preferen­
tial partitioning of proteins involved in cellular signaling events 
critical to cell viability [1]. In vivo, lipid rafts have been postulated to 
0005-2736/$ - see front matter © 2010 Elsevier B.V. All rights reserved, 
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be aggregates of phospholipids, cholesterol, and glycosphingolipids 
[2-6] associated with important biological processes such as 
endocytosis, signaling, protein transport, apoptosis, and cytoskeleton 
organization [7],
To maintain cell viability, there exist specific pathways that control 
membrane composition; one of them is the reverse cholesterol 
transport (RCT) pathway, the mechanism by which excess cholesterol 
is removed from peripheral cells [8,9], In order to occur efficiently, 
apolipoproteins as apolipoprotein A-I (apoA-l) must interact with key 
components at the plasma membrane in a process that is strongly 
dependent on protein conformation and membrane composition and 
heterogeneity.
This article reviews the use of fluorescence microscopy method­
ologies in the analysis of apoA-I and HDL interactions with artificial 
and natural membranes, as an example of the use of microscopy on 
this type of system.
2. The RCT cycle: apoA-I and reconstituted HDL particles (rHDL) 
interaction with membranes
Cholesterol is a key lipid component of biological membranes, and 
its content and partitioning between raft and more fluid domains can 
be modified in order to regulate several cellular processes as enzyme 
activity, signal transduction, opening/closing of channels [10], etc. By 
the Reverse Cholesterol Transport (RCT), human HDL transports 
excess cholesterol from peripheral tissues to the liver for excretion 
into bile and feces [11]. Many steps in the RCT are under investigation 
as possible therapeutic targets, in order to improve cholesterol efflux 
and thus reducing cardiovascular risk.
Even though the RCT pathway is not completely understood, it is 
believed that the first steps involve the interaction of lipid-free or 
lipid-poor apolipoproteins (for instance apoA-I) with the ATP Binding 
Cassette transporter ABCA1 at the plasma membrane. This event 
initiates the efficient removal of cholesterol and phospholipids, 
promoting the apoA-I rearrangement into disk-shaped particles 
(pre(3HDL). This process is unidirectional and requires ATP as an 
energy source, mediating not only removal of plasma membrane 
cholesterol but its mobilization from internal pools as well [12]. The 
prepHDL particles further remove lipids very efficiently from the 
plasma membrane, probably involving different mechanisms such as 
acceptors of spontaneously solubilized cholesterol, or specific inter­
action of apoA-I with other membrane proteins, such as ABCG1 [13]. 
Lipidated products serve as substrates for plasma Lecithin Cholesterol 
Acyltransferase (LCAT), and other lipid transfer proteins giving rise to 
circulating, mature HDLs, which are recognized by liver receptors and 
thus catabolized [14]. Passive diffusional lipid removal by HDL also 
contributes to ensure the efficiency of cholesterol homeostasis.
In support of the function mentioned for HDL in RCT, a substantial 
body of evidence agrees that high levels of circulating HDL inversely 
correlate with the risk of developing cardiovascular disease (CVD) [15]. 
Nevertheless, the efficiency of HDL to solubilize cholesterol, and/or to 
interact with key components of the RCT pathway, is strongly 
dependent on HDL particle stability, size, and chemical integrity 
[16,17]. HDL lipids and proteins can be subjected to cellular environ­
ments that induce oxidation, glycation, or other modifications, 
especially during systemic inflammation, diabetes, and chronic renal 
or coronary heart disease. In these cases, HDL becomes dysfunctional 
and loses many of its atheroprotective roles such as LCAT activation [18], 
inhibition of LDL oxidation [19], cholesterol efflux [20], etc. Thus, newer 
research suggests that the “dynamic flux" of macrophages-derived 
cholesterol through the RCT pathway is more important to determine 
risk of CVD than the steady-state concentration [11], and that the quality 
of the lipoproteins, rather than the quantity, should be considered in 
order to establish the predictable protective role of HDL [19].
In addition, the efficiency of apoA-I interaction with membranes 
and lipid removal depends not only on protein conformation but also 
on the heterogeneity of the membrane, which is believed to play a key 
role in the regulation of some of the steps involved [21]. Despite their 
enrichment in cholesterol, lipid rafts do not seem to be essential for 
lipid efflux mediated by apoA-I, since it was suggested that cholesterol 
is preferentially acquired from the loosely packed, “non-raft" micro­
domains [22,23]. Thus, it was proposed that one of the functions of the 
ABCA1 should be to induce a redistribution of cholesterol and 
sphingomyelin from rafts to non-rafts domains in order for them to 
be accessible to acceptors [21]. These studies support the following 
hypothesis: “the interaction of apoA-I and HDL with the cellular 
membrane, and its capacity to remove phospholipids and cholesterol 
is dependent on the composition and distribution of lipid domains in 
the plasma membrane".
By visualizing artificial models, we studied different aspects of 
these interactions using two-photon fluorescence microscopy. Ana­
logs of the pre(3HDL containing apoA-I and different molar ratios of 
lipids have been reconstituted, and interactions with model bilayers 
and cells were observed and quantified: our results clearly show that 
protein binding to bilayers is dependent on both protein conformation 
and membrane composition: we discuss here published and new data 
and the extrapolation of the in vitro data to in vivo systems with 
possible implications.
3. What can microscopy teach us about the apoA-I/HDL- 
membrane interaction?
3.1. Models for microscopy studies and fluorescence microscopy 
techniques
Although most of the lipid models systems available (SUVs, MLVs, 
LUVs, etc) can be used in microscopy studies, the most appropriate 
systems are planar membranes [24] and Giant Unilamellar Vesicles 
(GUVs), since they allow spatial resolution and visualization. This 
work is focused on the use of GUVs as model systems.
GUVs are constructed by the electroformation method published 
by Angelova and Dimitrov in 1986 [25] and the methodology 
published by Pott et al. [26,27], which allows GUVs to be grown at 
higher salt concentrations required for protein studies in solution.
GUVs can be produced from pure lipids, lipid mixtures, natural 
lipids extracted from cells, and also from entire membranes contain­
ing proteins and lipids. We will refer here to the methodologies and 
techniques used to study the influence of lipid segregation in the 
lipid-protein interaction, therefore most of the mixtures used show, 
under certain conditions of temperature and lipid composition, phase 
separation visible under the microscope.
Studies of lipid-protein interaction using systems that show 
separation of macrodomains address the hypothesis that in vivo 
membranes are heterogeneous and present segregation of lipid 
domains. Studies on cells indicate that the major portion of the 
plasma membrane is in the liquid-ordered state [28]: instead, the raft 
theory states that heterogeneity in the membrane is due to the 
existence of areas with ordered packing (lo phase) in a more fluid (ld) 
continuous phase. This idea comes from the discovery that glyco­
sphingolipids cluster in the Golgi apparatus before being sorted to the 
apical surface of polarized epithelial cells [2,29] and experiments 
showing that glycosphingolipid clusters tend to be insoluble in Triton 
X-100 at 4 °C, forming detergent resistant membranes (DRM) rich in 
both cholesterol and glycosylphosphatidyl inositol (GPI)-anchored 
proteins [30]. Rafts are theoretical structures postulated to exist in 
cellular membranes of similar compositions and phase (lo) of DRMs in 
equilibrium with the rest of the membrane in a more fluid phase (ld). 
Based on the composition of the DRMs, synthetic mixtures called raft­
like mixtures are used to reconstitute model membrane systems 
where lipid phases coexist [31-35], in order to study the influence of 
phase segregation on protein-lipid interaction. Fig. 1 shows a diagram
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Fig-1- Schematic representation for the experimental protocols used in the studies of lipid-protein interactions in Giant Unilamellar Vesicle system presenting phase coexistence. 
(A) Binding experiments are performed adding labeled protein to the chamber containing the GUVs. After the incubation period, the protein may preferentially bind to one or both 
types of domains. Different fluctuation techniques (described in the text) can be used to quantify the binding. Circular objects represent the top view of the GUV presenting lipid 
domains. (B) Laurdan GP imaging is used to detect changes in water content (related to membrane fluidity) in the lipid bilayer due to the interaction with proteins. After the 
interaction, the GP changes may occur in the two phases or in one of them, both the GP value and the size of the domain can be quantified and give information of the interaction. The 
ring shapes represent the GP image of a GUV taken at the equatorial plane and presenting domain separation (two different colors represent two macrodomains with different GP 
value), this configuration is preferred for GP quantification because all the Laurdan molecules (located parallel to the lipids) are excited by the circular polarized light usually used for 
excitation.
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describing the methodologies and techniques used in these types of 
studies.
Protein binding (Fig. 1A). GUVs presenting macrodomain separa­
tion can be used to assess the binding of a protein to a specific 
macrodomain. The protein under study (labeled with a fluorescent 
molecule) is added to the chamber containing the GUVs, and after the 
appropriate incubation period, measurements assessing for binding 
are performed. Several techniques are suited to extract information 
about binding: the first qualitative answer is given simply by 
fluorescence intensity measurements: in this case the intensity 
image can show homogeneous or domain-specific binding and the 
images will show a sphere (the GUV) totally fluorescent or fluorescent 
in some specific areas (see Fig. 1A, Possible Qualitative Answers). To 
assess the lipid phase where the protein preferentially binds, a 
membrane probe such as Laurdan or Prodan can be added to the same 
GUV after the binding has occurred, or if a dual emission channel 
system is available, the lipid phase is measured in one channel and the 
binding is measured in the other channel using fluorescent dyes with 
good emission spectral separation and the appropriate filters [36-38].
In addition, fluctuation techniques can be used to quantify the 
binding affinity, including Fluorescent Correlation Spectroscopy 
(FCS), scanning FCS (sFCS), Raster Image Correlation Spectroscopy 
(RICS), and Number and Brightness Analysis (N&B). FCS [39-43] 
measures the fluctuations in fluorescent intensity in a small volume 
generated by a pinhole in confocal microscopes or by the two-photon 
excitation process [44-46]. Fluctuations due to diffusion of the 
molecules in and out of the small volume are detected as a function 
of time and the Autocorrelation Function (ACF) Analysis gives the 
diffusion coefficient (Dcoef) and the average number of particles in the 
observation volume (N). The fluctuation can also be analyzed using 
PCH [47], where the probability of detecting photons per sampling 
time is calculated and thus the number of molecules in the 
observation volume (N) together with its molecular brightness (/3) 
is extracted. FCS measurements on the coexisting macrodomains of 
the GUVs can report the mobility (Dcoef) and the number of molecules 
of bound and free protein allowing the estimation of the dissociation 
constant. Scanning FCS [48] gives the same information as point FCS 
with the big advantage of allowing sampling of several points at the 
same time, and permits one to discriminate fluctuations coming from 
the movement of the GUV itself by cross-correlation analysis of points 
separated in space [49-51]. RICS [52] provides the same dynamic 
information as FCS as well as information on the spatial correlation 
between points along the scanning path. As the laser performs the 
raster scanning movement, it creates a space-time matrix of pixels 
within the image. The temporal and spatial sampling of the laser beam 
during the raster scanning is known, that is, the time the laser samples 
each pixel (pixel dwell time): the time between scan lines (line time): 
and the time between images (frame time). Therefore, the images 
contain information on the microsecond time scale for pixels along 
the horizontal scanning axis, millisecond time scale along the vertical 
scanning axis or between scan lines, and on the subsecond to second 
or longer time scale between successive images. This technique can 
provide maps of the diffusion coefficient and the number of molecules 
of the bound and free species. Number and Brightness (N&B) Analysis 
is based in moment analysis, for each pixel in an image stack [53,54]. 
From the average intensity in each pixel and the variance of the 
intensity distribution, the number and brightness (aggregation) of 
mobile particles is determined, thereby providing a new contrast 
mechanism in the images based on a molecular property. If the 
protein of interest aggregates when it binds to the membrane, this 
technique can accurately detect oligomerization [55].
Furthermore, all these techniques performed in a two-channel 
emission setup allow one to correlate protein binding and membrane 
phase and to ascertain the protein binding stoichiometry, etc. [56-58]. 
If the GUVs have been constructed with a fluorescent protein 
integrated to the bilayer, the same techniques will provide valuable 
information on motility and aggregation state of the protein 
immersed in the membrane [27,59].
Changes in membrane phases (Fig. IB). GUVs presenting lipid 
segregation can also be a good model to study the properties of lipid 
bilayers during protein interaction. Valuable information is given by 
the fluorescent dye Laurdan, used as a membrane probe because of its 
large excited state dipole moment, which results in its ability to report 
the extent of water penetration into the bilayer surface due to the 
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dipolar relaxation effect [60]. Water penetration has been correlated 
with lipid packing and membrane fluidity [61,62]. The emission 
spectrum of Laurdan is centered at 440 nm if the membrane is in the 
gel phase and at 490 nm when it is solubilized in the liquid crystalline 
phase. The Generalized Polarization (GP) value, defined as the 
difference of intensities at 440 minus 490 nm divided by the sum, 
measures the emission shift. To calculate the GP value in a two-photon 
microscope (to avoid photo-bleaching), an excitation wavelength of 
780 nm and a two-channel system with the corresponding filters on 
the emission are used [31,63].
In a GUV presenting phase separation, the emission of Laurdan will 
depend on the water content of each phase: the emission from a fluid- 
ordered phase is blue shifted, as compared with the emission from the 
fluid-disordered domain. In this way, spatial identification of coex­
isting phases can be realized directly from the GP image. Thus, 
Laurdan GP imaging [31,63,64] can quantify and localize changes in 
the packing of the lipids in the bilayer due to protein binding, 
cholesterol removal, etc. GP images are usually taken in the equatorial 
plane of the GUV [31,63]: in this configuration, all the Laurdan 
molecules located parallel to the phospholipids can be excited with a 
circular polarized light (Fig. IB). Under this condition, the GP images 
can be processed and the macrodomains separated and studied 
independently. The areas of each macrodomain can be quantified to 
study specific morphological changes associated with the interaction. 
These methodologies have been used for the study of several proteins 
[36-38,55,65-67] and the apoA-I/HDL system [68-72].
3.2. ApoA-I interaction with heterogeneous membranes
The idea that the interaction of apoA-I with membranes is favored 
by bilayer irregularities was suggested in 1978 by Pownall et al. [73] 
following the interaction of apoA-I with multilamellar DMPC 
liposomes by light scattering. The data showed a decrease in light 
scattering of the DMPC MLVs after addition of apoA-I (interpreted as 
lipid solubilization) only at 24.8 °C; the authors concluded that this 
behavior arises from the formation of a “structural determinant"
DMPC (24.8 C) DMPC:DSPC 1:1 (28 °C)
Intensity Intensity Intensity
DMPCrDSPC 1:1 (42 C)
alexa-apo A-l
Intensity
overlapping
Intensity
Fig. 2. ApoA-I interaction with heterogeneous membranes. (A) Membrane heterogeneities existing at the transition temperature [63]: Laurdan intensity image (top view) of a DMPC 
GUV at 24.5 °C attached to the platinum wire (structure on the right). (B, C) Lipid solubilization from DMPC:DSPC 1:1 GUVby apoA-I occurs at 28 °C [68] as evidenced by the decrease 
in volume of the GUV as comparing the Laurdan intensity image (B) before and (C) after incubation with apoA-I for 2 h. (D-F) ApoA-I binding to heterogeneous bilayers: a GUV made 
of DMPC:DSPC (0.35:0.65 molar ratio) at 42 °C. A target GUV was chosen using the CCD camera and the control image taken before the addition of the labeled protein showed 
background signal ~ 150 total counts (image not shown). After 2-h incubation with Alexa488-apoA-I, the (D) intensity image showed ~ 130,000 total counts defining the shape of the 
GUV, which indicates protein binding. Next, Laurdan was added to the chamber (final concentration of 0.76 pM) and the same target GUV was imaged (E) revealing the 
heterogeneities existing on the membrane (total counts increased 10 times with respect to D). (F) The overlapping of (D) and (E) showing that binding of the protein does not 
correlate with the membrane heterogeneities. No changes in the size of the GUV occurred at this temperature after adding apoA-I. Experiments were performed in a two-photon 
microscope previously described [68,70]. For both probes (Alexa488 and Laurdan) excitation wavelength of 780 nm was used and the fluorescence emission was observed through a 
broad band-pass filter from 350 to 600 nm (BG39 filter, Chroma Technology, Brattleboro, VT). Blue-red color scale is used for Laurdan intensity images and red for Alexa488.
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associated with coexisting gel and liquid crystalline phases, and this 
determinant was necessary for the efficient interaction. Later in 2007, 
two-photon microscopy studies done by our group showed that this 
“determinant" indeed exists at the phase transition of DMPC [63]. 
Fig. 2A shows the top view intensity image of a DMPC GUV at 24.5 °C 
(similar image of the already published [63]). Close to the transition 
temperature of DMPC, the lipid molecules in gel and liquid phases 
coexist and there is a large area of defects. The particular bilayer state 
existing at the transition temperature is characterized as having high 
stress, which induces volume and shape changes [74] and high 
permeation to small molecules [75]. This state could allow deeper 
penetration of some of the amphipatic helices of apoA-I, inducing a 
conformational rearrangement in the protein in which the hydro- 
phobic faces of the helices come into close contact with the acyl chains 
of the lipids favoring their removal.
In the interaction of apoA-I with binary mixtures, the efficiency of 
lipid removal is also dependent on a special membrane condition. 
Scattering measurements for MLVs of DMPC:DSPC also show a 
particular temperature at which lipids are solubilized (28 °C) [76]. 
In this regard, we have used DMPC:DSPC 1:1 molar ratio GUVs, and 
demonstrated that domain segregation is not the important factor for 
lipid solubilization by apoA-I. In these liposomes, domain coexistence 
is present from ~50 to 24 °C but effective lipid solubilization only 
occurs at ~28 °C [68]: this fact is detected by a decrease in the size of 
the GUV after addition of apoA-I (Fig. 2B and C) as a consequence of 
solubilization of both lipids from the binary mixture, but with higher 
preference for the more fluid component [68].
The preferential binding of apoA-I to areas of different lipid packing 
was assessed using Alexa488-labeled apoA-I (Alexa488-apoA-I) and 
GUVs of DMPC:DSPC (0.35:0.65 molar ratio) at 42 °C (temperature 
where phase coexistence exists). A target, unlabeled GUV was localized 
using a CCD camera and Alexa488-apoA-I was added to the chamber to a 
final protein concentration of lOpg/ml. After 2-h incubation, the 
intensity image (Fig. 2D) shows the GUV defined by the brightness of 
labeled apoA-I, indicating the binding of the protein to the bilayer. Next, 
Laurdan was added to the chamber and the same GUV was imaged. The 
Laurdan intensity image (Fig. 2E) evidences a membrane topology 
similar to the “structural determinant" associated with coexisting gel 
and liquid crystalline phases on DMPC (Fig. 2A); in this mixture the 
irregularities can be attributed to the coexistence of the DMPC and DSPC 
molecules, which at 42 °C are over and below their transition 
temperatures, respectively (Tm DMPC = 24 °C, Tm DSPC = 55 °C; 
Fig. 2E). Fig. 2F shows the overlapping of Fig. 2D and E evidencing the 
fact that apoA-I binding is not dependent on the lipid packing.
Similar results of homogeneous binding were obtained on POPC: 
SM:FC GUVs presenting phase separation [72]. Fig. 3 shows a diagram 
with the main conclusions of our published studies on the interaction 
of lipid-free apoA-I and membranes in vitro [63,68,70,72]: apoA-I is 
able to bind to the lipids in a homogeneous lipid phase (Fig. 3A, [64])
-20 0 20 40 60 80 100 120 140 160
time (minutes)
Fig. 4. Kinetics of cholesterol removal by particles of 96 A of wild type apoA-I rHDL 
(circles) [69] and of the mutant Hl @H4 (squares) at 36.5 °C from POPC-30% cholesterol 
GUVs. Solid line for the opened circle symbols corresponds to a first-order exponential 
decay fit with a time constant of 39.3 ± 0.1 min. GP images of the GUV at the beginning 
(top left) and end (bottom right) of the incubation time are also shown and colored 
according to the GP scale going from — 1 to 1.
but effective lipid solubilization occurs only under particular condi­
tions: either at the transition temperature of a pure lipid or where the 
membrane is composed of small fluid domains nucleated within a 
continuous gel phase (a few degrees above the melting temperature 
of the more liquid component in a binary mixture): under these 
conditions interfacial packing defects are maximal (Fig. 3B) [68].
3.3. Cholesterol efflux and Laurdan GP
ApoA-I constitutes -70% of the protein moiety of HDL and its 
conformation is highly flexible in order to rearrange in response to 
changes in HDL lipids during catabolism. Human apoA-I contains a 
series of highly homologous 11- and 22-residue amphipathic a- 
helices. These amphipathic a-helices are defined by the arrangement 
of positively and negatively charged amino acids on the helical polar 
face as classes A and Y. Helix lisa Class A helix together with helices 2 
and 5-8, which have positively charged amino acids surrounding the 
non-polar face with negative residues clustered at the center of the 
polar face. Helices 3-4 and 10 are class Y helices, organized similarly 
but having a positive charge disrupting the negative cluster [77]. 
Mutants lacking helix 10 show lower rates of cholesterol efflux and 
recently Panagotopulos et al. [78] have shown that helix 10 is critical 
for promoting optimal cholesterol efflux via the ABCA1 pathway from
A
Fig. 3. Scheme of the different interactions of lipid-free apoA-I with membranes analyzed by our technical approach. (A) Lipid-free apoA-I interaction with homogeneous 
phospholipid bilayers results in high binding but non-efficient lipid removal [70], (B) Efficient lipid solubilization occurs from bilayers having high interfacial packing defects, with 
small fluid domains nucleated within a continuous gel phase [68], In the diagram, the blue ribbon represents the lipid-free apoA-I, circles with two legs represent the phospholipids 
in disordered state (white) and ordered state (gray), respectively.
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A B
Fig. 5. Interaction of rHDL with phase coexisting GUV. (A) Diagram of the target GUV 
attached to the Pt wire. (B) GP image of the target GUV (top view) of DOPC:DPPC:FC 
(1:1:1 molar ratio) at 24.8 °C presenting l0 (orange) and ld (light green) separated 
phases, a small GUV on the top right can also be seen and the discontinuity on the right 
shows the place of attachment of the GUV to the platinum wire. For GP measurements, a 
GP image is taken on the center of the same target GUV and the GP values for each phase 
are shown in the figure (C) at time zero and (D) after 60-min incubation with 10 pg/ml 
96 A rHDL [69], False color representation according to the palette with GP values going 
from —1 to 1 is used.
RAW macrophages. Deletion of helix 1 also reduced lipid binding 
affinity [79].
As circulating HDL are composed of an heterogeneous and dynamic 
group of particles with different sizes, shapes, and compositions, 
models have been created in order to understand the conformational 
arrangement of apoA-I involved in lipid homeostasis. Thus, homoge­
neous lipoprotein complexes homologous to the preß HDL particles 
observed as the first intermediates of cholesterol solubilization [80] 
have been reconstituted (rHDL) with apoA-I and different amounts of 
cholesterol and phospholipids. These particles can be obtained by the 
sodium cholate method [70], or by spontaneous solubilization of lipids 
at the transition temperature.
The organization of apoA-I in the rHDL has been reviewed before 
and three models have been proposed: the picket fence [81], the belt 
[82], and the hairpin models [79]. Förster Resonance Energy Transfer 
(FRET) data from our previous studies strongly support the hairpin 
arrangement of apoA-I in these HDL complexes [83]. The three models 
agree that helices 10 and 1 are directly involved in the interaction of 
the HDL particles with the lipids in the bilayer. In order to determine 
the importance of helix 1 for protein interaction and cholesterol 
solubilization from membranes, we used an apoA-I mutant, H4@H1, 
having the putative high-lipid affinity helix 1 replaced with a second 
copy of a lower lipid affinity helix 4 [84] but which still has helix 10 in 
its normal location at the C terminus. The lipid-free mutant exhibited 
cholesterol efflux capabilities similar to Wt (wild type) on RAW 
macrophages: however, it exhibited markedly reduced (50%) lipid 
association characteristics in the DMPC clearance experiments. 
Reported changes in GP values of GUVs of POPC-32%cholesterol 
incubated with 78 A rHDL containing Wt apoA-I demonstrated that 
rHDL efficiently remove cholesterol from the lipid bilayer [69]. FCS 
data on the same system showed that the 78 A rHDL interact with the 
bilayer as independent units (constant number of particles) and that 
their size increase (Dcoef decrease) to 96 A, results also consistent with 
lipid removal [70,85]. Fig. 4 shows the comparison of the GP changes 
observed on POPC-32% GUV incubated with equal concentration of 
rHDL containing the Wt apoA-I and the H4@H1 mutant (with altered 
helix 1). Changes in the GP values during the incubation with the wild 
type protein rHDL are consistent with published data [69]: however, 
no changes in GP were observed during 2-h incubation of POPC-32% 
FC GUVs with the mutant rHDL (Fig. 4). The lipid-free H4@H1 
exhibited cholesterol efflux capabilities similar to Wt from RAW 
macrophages: however, as expected, it exhibited markedly reduced 
(-50%) lipid association characteristics in the DMPC clearance 
experiments. It could be possible then that lipid association is 
important in order to facilitate passive cholesterol diffusion through 
the aqueous medium.
3.4. HDL interaction with membranes having coexisting phases
In the process of cholesterol removal by HDL, the extent and 
direction of the net cholesterol movement will depend on the ratio of 
efflux to influx and is determined by the properties of the acceptor (the 
HDL particle) and the donor (the membrane) [86]. Factors reducing 
the packing density of lipid molecules have been proposed to enhance 
the rate of cholesterol transfer [87]. Results from “raft-like" mixtures 
show that HDL particles preferentially remove cholesterol from lipid 
domains characterized as liquid disordered (ld) [69]. Fig. 5 shows the 
results obtained using Laurdan GP imaging to study the interaction of 
DOPC:DPPC:FC (1:1:1 molar ratio) and rHDL at 25 °C. At this 
temperature, the phase diagram indicates that liquid-ordered domains 
(lo, rich in DPPC) coexist with ld domains (rich in DOPC), with 
cholesterol partitioning between the two phases [88]. Laurdan GP can 
differentiate lo from ld phase and Fig. 5B shows them in different colors 
(lo in orange and ld in light green): rHDL were added to the GUV at
A P rHDL [
Fig. 6. Scheme of the interaction of lipid-bound apoA-I (rHDL) with membranes analyzed by our technical approach. (A) rHDL interact with and solubilize phospholipids and 
cholesterol from homogeneous bilayers as independent units and growing in size according to FCS measurements. (B) If cholesterol is distributed in two phases with different 
packing (l0/ld), rHDL preferentially remove phospholipids and cholesterol from the more disordered (Id) domain [69]. As in Fig. 3, circles with two legs represent the phospholipids 
in disordered state (white) and ordered state (gray). Black elliptical shape with one leg represents the cholesterol molecules.
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Fig. 7. GP imaging in alive cells. (Top) Human red blood cells were labeled with 1 pM Laurdan for 15 min and imaged at 37 °C. (A) Laurdan spectral image corresponding to the 
overlapping of 19 images taken simultaneously at different emission wavelength while exciting Laurdan at 780 nm (taken in a Zeiss Meta 710). (B) Normalized emission spectrum of 
Laurdan in the erythrocyte membrane taken from the area encircled in red in (A). (Bottom) Using SimFCS, the pixels in the GP image can be separated in those located inside the cells 
(lowGP) and the ones corresponding to the plasma membrane (high GP). Analysis for (C-E) human erythrocytes and (F-H) HeLa cells are presented.
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25 °C and the GP value of each phase was measured before (Fig. 5C) 
and after (Fig. 5D) 1-h incubation period. The GP value of the ld phase 
decreased from 0.1 to 0.02, indicating cholesterol removal, while the lo 
remained unchanged [69]. Contrary to lipid-free apoA-I that requires a 
high surface of domain coexistence to remove lipids [68], lipid 
solubilization toward rHDL depends on the accessibility for cholesterol 
(defined by the particular characteristic of the lipids present at the 
bilayer). The diagram in Fig. 6 shows the possible underlying process of 
the interaction of rHDL with membranes containing cholesterol. In the 
POPC:FC (32%) (Fig. 6A), the unsaturations present in the acyl chains of 
POPC introduce kinks that limit the ability of cholesterol to order, to 
mix homogeneously, to reduce interfacial elasticity [89], and to lower 
the in-plane elasticity [90]. Cholesterol locates more superficially and 
thus desorbs better from the membrane to the aqueous interface and 
transfers to the rHDL. A similar situation is observed in the coexisting ld 
phase in the DOPC:DPPC:FC (1:1:1) system. The ld phase is enriched in 
the unsaturated phospholipid (DOPC) [88] and the kinks on the acyl 
chains facilitate the transfer of cholesterol and phospholipids to the 
rHDL (Fig. 6B). On the other hand, the coexisting lo phase is formed 
mainly by DPPC, which contains a chain structural motif similar to 
natural sphingolipids [89]. It has been suggested that cholesterol 
molecules can locate in this type of bilayer with part of their tail in the 
adjacent leaflet [91 ] allowing formation of tail-to-tail dimers [92], and 
then impeding its desorption (Fig. 6B).
3.5. HDL interaction with cell membranes
Visualization of protein interactions with lipid domains in vivo is 
difficult due to the fast dynamics of lipid arrangement in membranes 
and the lack of methodologies to visualize membrane heterogeneity 
[5]. Thus, the most common methodologies used to study this type of 
interactions are the isolation of detergent resistant membranes 
(DRMs) [10] and the use of fluorescent dyes on fixed cells [28]. In 
the Keystone Symposium on Lipid Rafts and Cell Function in 2006 
[93], rafts were defined as “small (10-200 nm), heterogeneous, highly 
dynamic, sterol- and sphingolipid-enriched domains". Laurdan GP 
imaging have been used in the search for cell membrane heteroge­
neity in erythrocytes [94,95] and macrophages [96].
Erythrocytes are well-studied systems. Human erythrocytes were 
labeled with 1 pM Laurdan and Fig. 7A shows the spectral image 
corresponding to the overlap of 19 images taken simultaneously at 
different emission wavelengths while exciting Laurdan at 780 nm. 
Fig. 7B shows the spectrum corresponding to Laurdan inside the 
erythrocyte membrane. The spectrum centered at 440 nm indicates 
that membrane lipids are in an ordered phase in this system. In a 
microscope, a GP image (Fig. 7C) is obtained using two-photon 
excitation at 780 nm, two interference filters in the emission centered 
at 440 and 490 nm, and applying the GP formula pixel by pixel [31,63].
The GP image of human erythrocytes in Fig. 7C shows areas in the 
cells with different GP values. Using the SimFCS program (www.LFD. 
uci.edu), the pixels with low GP values ( —1 <GP<0.3) corresponding 
to the interior of the cells (Fig. 7D) can be separated from the pixels 
with high GP values (0.3<GP<l) corresponding to the plasma 
membrane (Fig. 7E). The GP image corresponding to the plasma 
membrane (Fig. 7E) shows no visible macrodomain separation in 
agreement with previous results reported by Bell's group [94,95]. 
Fig. 7F shows the GP image of a nucleated cell (HeLa cell) labeled with 
1 uM Laurdan. The separation of the pixels corresponding to the 
cytosol (Fig. 7G) and the ones from the membrane (Fig. 7H) also 
indicate the lack of macrodomain separation in the membrane of HeLa 
cells (Fig. 7H). Interestingly, the nuclear membrane cannot be 
distinguished from the rest of the cytosol indicating that the nuclear 
membrane is more fluid than the plasma membrane.
It seems to be an apparent contradiction between the data 
presented here reporting the lack of macrodomain separation in cell 
membranes and data reported by Gaus et al. [96]. These authors 
reported the 3D projection GP image of a macrophage showing 
extended areas with high GP values localized in knob-like membrane 
protrusions. The authors discussed that these areas could be either 
large rafts exclusive of this cell type, or areas enriched in small rafts 
A B
Fig. 8. Effect of cholesterol acceptors on the GP membrane of alive cells. (A) GP membrane values for human erythrocytes in buffer (Control), incubated with MpCD 3.5 mM for 
120 min, and incubated with 96 A rHDL 300 pg/ml for 2 h. Buffer used: 10 mM phosphate, 147 mM NaCl, 3 mM KC1, pH 7.4. (B) GP membrane values for HeLa cells in culture media 
(Control), incubated with M(3CD 10 mM for 60 min and incubated with 96 A rHDL 300 pg/ml for 2 h. Temperature for all the experiments was 37 °C and N corresponds to the 
number of cells analyzed. ANOVA test was performed to compare the control data and the data after incubation with the cholesterol acceptors. Results show a significant difference 
with p<0.05. Images presented correspond to the complete GP image. Palette shows the color scale used for all the images.
-1 AVERAGE GP 1
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with high GP. Our results in several nucleated cells show similar 
macroscopic regions of different GP. Most cells present evaginations, 
filopodia, and protrusions. In the 3D projection, these areas appear to 
have consistently higher GPs than in the rest of the cell. When we 
carefully separate the protrusions from the rest of the plasma 
membrane, we found that pixels belonging to the non-protrusive 
part of the plasma membrane are relatively homogeneous in GP value 
without evident separation into macroscopic domains. The fact that 
macrodomains are not visible by GP imaging in the relatively flat part 
of the plasma membrane does not exclude the existence of domains 
smaller than the pixel size. If these domains are also highly mobile 
[93], other techniques capable of capturing the fast dynamics will be 
needed to visualize them [5,50].
We report here the use of these two cellular systems (erythrocytes 
and HeLa cells) and the GP imaging technique to study cholesterol 
removal from the plasma membrane by rHDL and methyl beta cyclo 
dextrines (M(3CD). When human erythrocytes are incubated with 
3.5 mM M(3CD for 2 h at 37 °C, approximately 90% of the total 
cholesterol [97] is removed, inducing a decrease in GP of 0.1 unit 
(Fig. 8A). The same decrease in GP is obtained when erythrocytes are 
incubated with 300 pg/ml rHDL for 2 h at 37 °C. As seen in the images 
in Fig. 8A, we found that M(3CD induces changes in shape of the cells 
(Fig. 8A, second image from the left) as previously reported [94]. 
Instead, the use of rHDL as cholesterol acceptor was less damaging for 
the cells and changes in shape were not observed (Fig. 8A, third image 
from the left). Incubation of HeLa cells with 10 mM M(3CD for 60 min 
[98] induces the same changes in GP as incubation with 300pg/ml 
rHDL for 2 h at 37 °C. Both types of cells shown in Fig. 8 lack 
(erythrocytes) or have minor (HeLa cells) expression of the ABCA1 
transporter. Studies done by our group [99] using CHO (Chinese 
Hamster Ovary) cells (which express ABCA1) show a similar behavior 
than the one described for erythrocytes and HeLa. Nevertheless, as 
cells were not previously loaded with cholesterol, it is possible that 
ABCA1 was not highly activated under our experimental conditions. 
Interestingly, working with HeLa overexpressing ABCA1, Zarubica et 
al. [100] reported that overexpression of functional ABCA1 triggers 
not only apoA-I but M(3CD-mediated cholesterol efflux. They 
attributed this fact to a participation of ABCA1 in the redistribution 
of membrane-associated cholesterol into pools readily accessible to 
external acceptors.
The fact that GP imaging of the plasma membrane does not show 
macrodomain separation still leaves open the possibility that domains 
are smaller than the pixel size. If domains smaller than the pixel size 
indeed exist in cell membranes, the mechanism behind the decrease 
in GP value when cholesterol is removed (Fig. 8) has to be explained 
considering that the average membrane GP measured corresponds to
GP = (GPld x/ld) + (GP|O x/lo)
where GPld, GP1O, and fld, flo are the GP and the fraction (number of 
pixels) of the ld and lo phases, respectively [63]. Thus, the average GP 
value measured in the membrane is the result of cholesterol 
equilibrium between the membrane and the internal cholesterol 
storage, etc. Further studies are needed to understand the cellular 
mechanism behind these observations in relation to lipid segregation 
in cell membranes and the connection between the changes in 
membrane fluidity and cholesterol equilibrium.
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